Press Releases

June 1, 2023
STOUGHTON, Mass. , June 01, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc.  (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a
May 4, 2023
– Generated Record Net Revenue of $144.8 Million – – Delivered Record Belbuca ® and Xtampza ® ER Net Revenue – – Ended Q1’23 with Cash Balance of $269.5 Million – – Reaffirmed Full Year 2023 Guidance – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass.
April 20, 2023
STOUGHTON, Mass. , April 20, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc.  (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report first quarter 2023
April 11, 2023
STOUGHTON, Mass. , April 11, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc.  (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a
February 23, 2023
– Generated Record Quarterly and Full-Year Net Revenue of $129.6 and $463.9 Million –         – Ended 2022 with Cash Balance of $173.7 Million – – Reaffirmed 2023 Financial Guidance – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass. , Feb.
February 22, 2023
Highlights 2022 environmental, social and governance achievements STOUGHTON, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) --  Collegium Pharmaceutical, Inc.  (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced the release of its inaugural Environmental, Social and
January 4, 2023
– Product Revenues, Net Expected in the Range of $565.0 Million to $580.0 Million – – Adjusted Operating Expenses* Expected in the Range of $135.0 Million to $145.0 Million – – Adjusted EBITDA* Expected in the Range of $355.0 Million to $370.0 Million – – $100 Million Share Repurchase Program